← Back to Search

CAPS Program for Autism (CAPS Trial)

N/A
Waitlist Available
Research Sponsored by Drexel University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, month 3, month 12
Awards & highlights
No Placebo-Only Group

Summary

This trial will develop and test a novel support service for autistic adults to improve their health and well-being, leveraging existing infrastructure and input from experts.

Who is the study for?
This trial is for English-speaking autistic adults aged 18-30 living in Philadelphia County, who want to improve their social or daily life skills and have a confirmed autism diagnosis. Participants must be able to give informed consent and express challenges in major life areas like social interactions or work.
What is being tested?
The CAPS program is being tested, which is peer support given by individuals with lived experience of autism. The study aims to develop this novel service further and assess its effectiveness through a pilot randomized controlled trial before larger-scale implementation.
What are the potential side effects?
Since the intervention involves peer-support rather than medication, traditional side effects are not applicable. However, participants may experience varying degrees of emotional discomfort during discussions or while receiving feedback from peers.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, month 3, month 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, month 3, month 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Cognitive Flexibility
Change in Hope
Change in Internalized Stigma
+11 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: experimental armExperimental Treatment1 Intervention
Individuals who receive CAPS
Group II: controlActive Control1 Intervention
Individuals who receive treatment as usual

Find a Location

Who is running the clinical trial?

Drexel UniversityLead Sponsor
154 Previous Clinical Trials
48,166 Total Patients Enrolled
10 Trials studying Autism Spectrum Disorder
21,139 Patients Enrolled for Autism Spectrum Disorder
Temple UniversityOTHER
315 Previous Clinical Trials
88,913 Total Patients Enrolled
3 Trials studying Autism Spectrum Disorder
636 Patients Enrolled for Autism Spectrum Disorder
National Institute of Mental Health (NIMH)NIH
2,908 Previous Clinical Trials
2,739,043 Total Patients Enrolled
85 Trials studying Autism Spectrum Disorder
41,252 Patients Enrolled for Autism Spectrum Disorder

Media Library

CAPS Clinical Trial Eligibility Overview. Trial Name: NCT05702658 — N/A
Autism Spectrum Disorder Research Study Groups: experimental arm, control
Autism Spectrum Disorder Clinical Trial 2023: CAPS Highlights & Side Effects. Trial Name: NCT05702658 — N/A
CAPS 2023 Treatment Timeline for Medical Study. Trial Name: NCT05702658 — N/A
~12 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top